Regenerative Medicine Approaches for Age-Related Muscle Loss and Sarcopenia: A Mini-Review

Juan Diego Naranjo\textsuperscript{a,c} Jenna L. Dziki\textsuperscript{a,b} Stephen F. Badylak\textsuperscript{a–c}

\textsuperscript{a} McGowan Institute for Regenerative Medicine and \textsuperscript{b} Department of Bioengineering, University of Pittsburgh, and \textsuperscript{c} Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Introduction

Aging is associated with the progressive and predictable changes that occur in the human body. All body systems are affected by the aging process, compromising both general health and quality of life. The musculoskeletal system is no exception. In healthy young individuals, skeletal muscle protein synthesis and degradation is a balanced, dynamic process typically involving no net change occurring in skeletal muscle mass [1, 2]. However, muscle tissue mass is gradually lost with advancing age, with an...
Age-Related Muscle Loss and Sarcopenia

Skeletal Muscle Anatomy, Physiology, and Acute Regeneration following Injury

Skeletal muscle is composed of muscle fibers which are highly specialized to produce force and movement. These fibers are cylindrical in shape, range in diameter from 10 to 100 μm, contain multiple nuclei, mitochondria, and sarcomeres, and are surrounded by the basal lamina, i.e. the endomysium. Satellite cells represent the putative skeletal muscle progenitor cell type and reside between the basal lamina and the sarcolemma, though multiple cell types have been shown to provide myogenic potential, including perivascular stem cells [6–15]. Muscle fibers are arranged together in parallel and collectively form the muscle fascicle or fiber bundle which is encapsulated by a perimysium. A distinct muscle is formed by enveloping a large number of muscle fascicles in a thick collagenous external sheath extending from the tendons called the epimysium (Fig. 1). Multiple skeletal muscle fibers are innervated by a single α motor neuron (MU). Individual motor axons branch within muscle to synapse with different fibers over a wide area which helps promote even distribution of contractile force. The branching arrangement preserves muscle function even if individual MUs are damaged. The α MU and its associated muscle fibers are considered the smallest unit of force that can be activated in muscles to produce movement.

Skeletal muscle possesses an inherent capacity for regeneration following injury. This regenerative property is largely due to activation of resident satellite cells and is regulated in part by host innate immune responses, especially the macrophage response. Muscle injury is immediately followed by an inflammatory phase characterized by the recruitment of neutrophils and monocytes to the site of injury. Macrophages are activated and transition from a proinflammatory, M1-like phenotype that initiates skeletal muscle progenitor cell proliferation/expansion to a proremodeling, M2-like macrophage phenotype that is required for skeletal muscle progenitor cell mobilization and differentiation, deposition of new extracellular matrix (ECM), angiogenesis, and return to homeostasis. Disturbances in the responding stem/progenitor cell populations as well as the innate immune system and the microenvironment have been shown to contribute to sarcopenia [16]. Beyond aging, muscle wasting is also associated with chronic inflammatory diseases, including chronic obstructive pulmonary disease, muscular dystrophy, idiopathic myopathies, and rheumatoid arthritis, among others. Proinflammatory cytokines including IFNγ, IL-1, TNFa, IL-6, IL-18, and IL-8 have been shown...
to be major contributors to muscle loss in these and other chronic inflammatory disease states. Deleterious effects of inflammation inhibit efficient skeletal muscle regeneration and lead to muscle atrophy [17].

**Pathophysiology of Sarcopenia**

The onset of sarcopenia typically results from a combination of risk factors and is associated with a decreased skeletal muscle fiber number [18, 19], changes in the cross-sectional area of the remaining fibers [18, 20, 21], and systemic changes that alter normal muscle physiology. The potential contributing factors to the onset and progression of sarcopenia are reviewed below.

**Defects in Protein Trafficking, Degradation, and Removal**

The gradual and cumulative accumulation of nonfunctional muscle protein has been proposed as a potential mechanism by which sarcopenia occurs. This accumulation of nonfunctional protein is supported by the observation that the decrease in muscle strength is disproportionately greater than the decrease in muscle mass during the progression of sarcopenia. Potential causes of muscle strength mass and strength loss include defects in autophagy, ubiquitination, and lysosomal degradation, and decreased proteasome activity. Wohlgemuth et al. [22] showed an age-related impairment of autophagy that can be attenuated by caloric restriction alone or with voluntary exercise. Carnio et al. [23] demonstrated that inhibition of autophagy exacerbates aging phenotypes and has a major impact on neuromuscular synaptic function, muscle strength, and the life span of mice. Autophagy defects appear to relate to morphological changes in muscle fibers. For example, accumulation of p62/SQMT1, an indicator of lack of autophagy, is associated with smaller cross-sectional areas of muscle fibers when compared to p62/SQMT1-negative cells in aged mice [21].

Ineffective removal of nonfunctional proteins may be part of the etiology of the disease [24]. Similarly, oxidized proteins, which accumulate with advancing age, may not be as efficiently removed by normal ubiquitination and lysosomal degradation, resulting in the accumulation of lipofuscin and cross-linked proteins. Proteasome activity declines with age as the enzyme complex is progressively inhibited by oxidized and cross-linked protein aggregates. Thus, cellular aging in sarcopenia can be a result of mitochondrial oxidant production and a concomitant decline in proteolytic activity, both of which contribute to rapid accumulation of oxidized proteins, cellular dysfunction, and senescence [25].

**Mitochondrial Contribution to Sarcopenia**

Mitochondrial reactive oxygen species generation is increased in skeletal muscle during aging and is associated with impaired mitochondrial function and oxidative damage [26]. In healthy muscle, the potentially deleterious effects of reactive oxygen species are mitigated or regulated by expression of protective proteins [27]. This regulatory response is attenuated in aged mice and contributes to age-related loss of muscle mass and function [27]. Studies in rats and nonhuman primates have shown that mitochondrial DNA (mtDNA) mutations and deletions...
are increased in fibers from aged skeletal muscle, and these mutations are more frequent in muscles prone to sarcopenia [28].

mtDNA deletion mutations in skeletal muscle which clonally accumulate across individual fibers have been suggested as a mechanism for muscle wasting and associated decline in functional activity. Wang et al. [29] demonstrated that short, transient, systemic, double-strand breaks in mtDNA led to muscle wasting and a decline in locomotor activity in mice later in life with a significant decline in the number of satellite cells. It was later suggested that the contribution of mtDNA damage to sarcopenia could also involve the electron transport chain with an initial mtDNA mutation resulting in clonal accumulation of a mutation within the affected muscle fiber. Clonal accumulation of mutations within muscle fibers leads to alterations in the electron transport chain resulting in muscle fiber apoptosis and loss [30]. Herbst et al. [31] induced mitochondrial biogenesis with β-GPA (guanidino-propionic acid) pharmacologically in older-age mice which would promote clonal expansion of mitochondria and their already present mtDNA deletions/mutations. Treatment with β-GPA increased the number abnormal fibers in the electron transport chain and fibrosis and decreased muscle fiber number and mass. Increased numbers of mtDNA mutations have been shown in mice, rats [28], nonhuman primates [32], and humans. [33].

Loss of the Inherent Regenerative Capacity

The series of well-defined processes that promote myogenic regeneration include initial myofiber necrosis, infiltration of neutrophils and proinflammatory macrophages, myogenic progenitor cell proliferation, a transition toward proremodeling macrophages, myogenic progenitor cell differentiation, and eventual fusion and reinervation of regenerating muscle fibers [34]. Age-related changes in both the microenvironment and the myoblasts can hinder these important processes in individuals with sarcopenia.

Barberi et al. [16] showed that with age the changes in the microenvironmental niche are associated with: (1) satellite cells that are delayed in their response to activating stimuli in a suboptimal environment, and (2) iso-chronic conditions that can inhibit satellite cell differentiation. The pronounced loss of satellite cells in sarcopenic muscle [35] has led to the hypothesis of a cause-effect relationship between satellite cell number and muscle function with sarcopenia. However, murine studies have not consistently supported this theory [36]. Furthermore, Fry et al. [36] have shown that selective depletion of satellite cells did not contribute to sarcopenia, suggesting that satellite cell replenishment may not necessarily benefit affected patients.

Shefer et al. [37] demonstrated that although there may be a reduction in the number of satellite cells present in an aging environment, it is more likely that their impaired regenerative potential is caused by the environment and not by an inherent change in the cells themselves. Carlson et al. [38] disclosed through heterochronic experiments that old muscle cells can successfully regenerate when implanted into a younger host and vice versa. This process was validated further in experiments by Conboy et al. [39], which indicated that a mutual circulatory system can rejuvenate aged progenitor cells simply by exposure to a younger environment.

It is important to recognize the importance of the immune system in skeletal muscle regeneration. Teixeira et al. [40] reported that neutrophil depletion inhibited muscle regeneration, and Benze et al. [41], among others, have revealed that the acute regenerative response is highly regulated by the responding macrophage population. The presence of proinflammatory versus proremodeling macrophages changes the dynamics of muscle regeneration. Without an appropriate temporal macrophage phenotype transition, skeletal muscle regeneration does not occur [42].

Denervation Atrophy

One potential cause of sarcopenia is the loss of a MU input to the muscle [43]. As the number of functional motor units decreases with age, there is an enlargement of the cross-sectional area of the remaining units [44]. This motor unit remodeling occurs by selective denervation of muscle fibers, mainly fast-twitch (type IIB) fibers, followed by re-innervation from juxtaposed innervated units [45]. This process leads to a net loss of fibers and functional motor units and to an increase in motor unit size and single action potential amplitude [46]. It is not clear if the loss of MUs precedes the fiber number loss, or if the opposite occurs. Age-related loss of muscle mass has been shown to involve a greater loss of fast-fiber cross-sectional area [19], which is accompanied by a reduction in fast MUs [46]. Skeletal muscle appears to compensate for this reduction in MUs by hypertrophy of remaining smaller and slower MUs [46], thus partially explaining the presentation of slow muscle fibers in aging. Reduction in motor unit number is associated with histological changes such as angulated fibers and fiber-type clumping, both of which are suggestive of neuronal remodeling in elderly people [47]. It should be noted, however, that only
11% of specific force decrements are due to denervated fibers in rats, suggesting that other factors contribute to the development of sarcopenia [48].

Other neurologic changes can contribute to the development of sarcopenia, including a decrease in the number of nerve terminals, fragmentation of the neuromuscular junction, decrease in the neurotransmitter release, and a decreased number of acetylcholine receptors.

**Endocrine Changes in Sarcopenia**

Age-related changes in the endocrine system have been linked to sarcopenia; a finding that has both therapeutic and causation implications [reviewed in 49]. Serum testosterone levels decline with age in both men and women, and this decline is associated with decreased muscle mass and strength, especially in men [50]. Testosterone is the main anabolic hormone for protein synthesis in skeletal muscle and has been shown to promote muscle regeneration via satellite cell activation [49]. In several multicenter trials called “The Testosterone Trials”, 790 men of at least 65 years of age were treated with testosterone gel or placebo gel for 12 months. The percentage of men who had an increase of at least 50 m in 6-min walking distance was significant when participants of the 3 trials were compared (20.5% after testosterone vs. 12.6% after placebo, \( p = 0.003 \)). Treatment was well tolerated and with a similar rate of adverse events in the two groups [51].

Similarly, in females, menopause is associated with a marked reduction in estrogen levels and an accelerated decline in muscle mass and strength [52]. Estrogens have beneficial effects on muscle strength and are known to modulate the inflammatory response and response to injury in skeletal muscle through satellite cell activation and proliferation [53]. Hormone replacement therapy in women appears to delay muscle loss with age and accumulation and increase in skeletal muscle fat [54].

**Vitamin D, Insulin, and IGF-1: Implications in the Pathogenesis of Sarcopenia**

Vitamin D is typically administered for skeletal disorders, but modulation of muscle morphology, muscle strength, and physical performance has also been reported [55]. The mechanism by which vitamin D exerts protective effects in skeletal muscle remains unclear. Vitamin D supplementation in vitamin D-deficient elderly people resulted in improved muscle strength ability and a reduction in falls and fractures [56].

Insulin sensitivity declines with age in several tissues, including skeletal muscles [57]. Insulin decreases protein degradation and stimulates protein synthesis [58]. An increase in insulin resistance with age could result in inhibition of the nitric oxide cascade which would result in a lower absorption of amino acids for protein synthesis. Diabetes mellitus is a condition that is frequently associated with sarcopenia in the elderly [59]. Diabetes mellitus promotes the reduction in muscle mass and strength through hyperglycemia, obesity, and increased general inflammation, all of which are known risk factors for sarcopenia [59].

Growth hormone and insulin-like growth factor-1 (IGF-1) are potent stimulators of cell proliferation, and both factors progressively decrease with age in adults due to progressive functional impairment of the hypothalamic-pituitary axis. Growth hormone production has been reported to decline with age with a parallel decline in IGF-1 secretion [60]; this decline contributes to several detrimental phenotypes of aging. IGF-1 is the primary mediator of muscle repair and growth which stimulates satellite cell proliferation and muscle protein synthesis, inhibits proteolysis, and counteracts inflammation and fibrosis [61]. Decreased serum IGF-1 levels and low bioavailable testosterone are independently associated with the risk of developing sarcopenia [62].

**Current and Potential Novel Approaches to Sarcopenia Treatment**

**Exogenous Stem/Progenitor Cell Delivery**

Prior to age-related changes, skeletal muscle tissue maintains a remarkable capacity to regenerate following acute injury. After injury, the quiescent stem cells that reside between the basal lamina and sarcolemma are activated, proliferate, and replenish the satellite cell pool or fuse and differentiate to form multinucleated myofibers. The association of sarcopenia with loss of these functional contractile myofiber units has logically prompted the investigation of utilizing exogenous delivery of stem/progenitor cells to repopulate the satellite cell pool and stimulate myogenesis. To date, little success has been achieved by exogenous stem cell delivery. Table 1 lists the different cells that have been evaluated for skeletal muscle repair. However, stem cell-based approaches for skeletal muscle regeneration are plagued with issues of deliverability and in vitro expansion. While preclinical studies continue to show promising results, the clinical utility of stem-cell-based approaches must circumvent not only technical but also economic and regulatory hurdles prior to their widespread adoption as a therapy for sarcopenia.

Naranjo/Dziki/Badylak
Biologic Scaffolds

Technical, regulatory, and economic issues have prevented timely translation of both stem-cell-based and pharmacological approaches to sarcopenia treatment. Inherently, skeletal muscle tissue has the ability to regenerate following acute injury, a property mostly attributed to the activity of satellite cells. However, it is becoming better understood that, in fact, the microenvironmental niche plays a significant role in contributing to the proliferative capacity of satellite cells and regeneration of skeletal muscle as a whole [16]. When skeletal muscle regenerative capacity is impeded, it is likely due, at least in part, to the loss of inherent signals that contribute to skeletal muscle regeneration in healthy tissue.

The evidence that changing the environment of aged myogenic progenitor cells can promote skeletal muscle regeneration is overwhelming. Moreover, clinical evidence indicates that mother nature’s ideal microenvironment, healthy ECM in the form of a biologic scaffolds, promotes myogenesis in patients with volumetric muscle loss. In studies by Dziki et al. [63], the resultant muscle formation was not only histologically similar to that of uninjured muscle tissue, but patients treated with ECM bioscaffolds demonstrated notable strength and func-

---

### Table 1. Stem-cell-based strategies for myofiber regeneration

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Description</th>
<th>Progress towards therapeutic potential</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satellite cells [6, 7]</td>
<td>Adult stem cells, Express Pax7 transcription factor</td>
<td>50 years from first identification to a pure cell isolation. Surface markers identified for satellite cell isolation are not necessarily reflected in human physiology. Need for optimized isolation and more efficient expansion.</td>
<td>Very difficult to isolate and expand in culture. Limited engraftment efficiency</td>
</tr>
<tr>
<td></td>
<td>Necessary for proliferation and maintenance of muscle stem cell pool</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle-derived stem cells [8, 9]</td>
<td>Adult stem cells, Identified in the interstitial space in mice, Nonadherent cell population</td>
<td>Improve muscle regeneration as measured by histology in preclinical murine models. Can be expanded in vitro up to 30 passages while retaining myogenic capacity.</td>
<td>Poor engraftment efficiency. No functional improvement despite histological improvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perivascular stem cells [10, 11]</td>
<td>Adult stem cells, Found in muscle microvasculature typically vessel associated CD146+/NG2+/ALP+, Express satellite cell markers, Assume satellite cell position after injection</td>
<td>Currently ongoing phase I/II clinical trial for pediatric muscular dystrophy. Can be cultured up to 20 passages while retaining myogenic capacity.</td>
<td>Variability in in vitro scalability gives them a finite culture life span</td>
</tr>
<tr>
<td>Embryonic stem cells [12 – 14]</td>
<td>Pluripotent cells isolated from inner cell mass of blastocyst</td>
<td>Generation of large quantities in vitro is possible. Engraftment ability has been demonstrated in murine models.</td>
<td>Difficult to recapitulate the skeletal muscle lineage in vitro. Potential immunologic mismatch. Ethical concerns</td>
</tr>
<tr>
<td>Induced pluripotent stem cells (iPSC)</td>
<td>Genetically reprogrammed somatic cells inducing a pluripotent state</td>
<td>Generation of Pax7+ iPSCs is possible. Generation of functional, human skeletal myogenic progenitors has been accomplished.</td>
<td>Requirement for genetic correction. Risk of tumor generation</td>
</tr>
</tbody>
</table>

---

*Biologic Scaffolds*

Technical, regulatory, and economic issues have prevented timely translation of both stem-cell-based and pharmacological approaches to sarcopenia treatment. Inherently, skeletal muscle tissue has the ability to regenerate following acute injury, a property mostly attributed to the activity of satellite cells. However, it is becoming better understood that, in fact, the microenvironmental niche plays a significant role in contributing to the proliferative capacity of satellite cells and regeneration of skeletal muscle as a whole [16]. When skeletal muscle regenerative capacity is impeded, it is likely due, at least in part, to the loss of inherent signals that contribute to skeletal muscle regeneration in healthy tissue.

The evidence that changing the environment of aged myogenic progenitor cells can promote skeletal muscle regeneration is overwhelming. Moreover, clinical evidence indicates that mother nature’s ideal microenvironment, healthy ECM in the form of a biologic scaffolds, promotes myogenesis in patients with volumetric muscle loss. In studies by Dziki et al. [63], the resultant muscle formation was not only histologically similar to that of uninjured muscle tissue, but patients treated with ECM bioscaffolds demonstrated notable strength and func-
tional improvements in addition to electromyographic improvement. Furthermore, ECM bioscaffolds have consistently been associated with a more favorable macrophage activation state transition in myogenic animal models [64]. Therefore, ECM bioscaffolds may represent an attractive solution for the treatment of age-related muscle loss. By providing the appropriate tissue niche and directing the macrophage response, ECM bioscaffolds can alter the default response to skeletal muscle injury and may provide an inductive template for facilitating muscle regeneration in an elderly host.

Although bioscaffolds have been implanted by invasive surgical procedures, minimally invasive delivery of the bioactive components of these bioscaffolds is possible. ECM hydrogels, which retain the composition and bioactivity of the intact ECM, would enable minimally invasive delivery of ECM via syringes or catheters [65]. Matrix-bound nanovesicles have recently been identified within ECM bioscaffolds. These nanosized particles appear to be one of the main signaling mechanisms by which biologic effects are elicited within tissue. These matrix-bound vesicles have great potential as a minimally invasive treatment strategy [65].

**Pharmacological Approaches**

Pharmacological approaches to muscle regeneration have traditionally focused upon the delivery of anti-inflammatory drugs, steroids, hormones, and growth factors, for example. These approaches may hold promise in reverting the functional decline of sarcopenia or improving outcomes, but they do not specifically target myogenesis or directly affect the restoration tissue function. Drug delivery methods remain a significant obstacle. Systemic delivery of pharmaceuticals limits their efficacy due to the requirement of a suboptimal dose to avoid toxicity and other systemic side effects. The short half-life of most pharmaceuticals renders direct injection of the drug into the targeted muscle compartment generally ineffective [66]. Controlled drug delivery approaches have been the subject of active investigation in an attempt to deliver the appropriate dose of promising drugs to promote myogenesis.

Recently, it has been shown that a particular peptide expressed in the central nervous system and peripheral tissues, urocortin II, has potential as a therapeutic agent for muscle loss due to sarcopenia [67]. The link between urocortin II and muscle loss due to aging involves the relationship between sarcopenia, insulin resistance, obesity, and diabetes. Skeletal muscle relies heavily upon glucose as an energy source. Because of the mass of skeletal muscle, insulin resistance has substantial systemic effects for this tissue [68]. Insulin-associated accretion of muscle mass has established a link between molecules like urocortin II, vitamin D, and myostatin to age-related muscle loss. The potential of insulin resistance in muscle tissue and sarcopenia to present as comorbidities may help elucidate overlapping dysregularities in each case and contribute to better understanding of sarcopenia and the development of improved pharmacological therapies.

Myostatin is an autocrine cytokine that inhibits muscle development and is expressed exclusively in skeletal muscle, preferentially in fast-type skeletal muscle fibers [69]. In a study that compared wild-type versus myostatin-null mice, myostatin was shown to play an active role in myogenesis regulation during aging [70]. The administration of a myostatin antagonist produces a short-term blockade of myostatin and an associated significant enhancement of muscle regeneration in aged mice after injury and during sarcopenia. Antagonism of myostatin was associated with satellite cell activation, increased Pax7 and MyoD levels, and greater myoblast and macrophage cell migration, all of which contribute to enhanced muscle regeneration after notexin injury in aged mice [71]. In men, higher serum myostatin was independently associated with higher odds for sarcopenia [72], which suggests myostatin antagonists as a potential therapy for sarcopenia.

**Muscle Loading and Exercise**

To date, the primary treatment option for sarcopenia is exercise, specifically load-bearing activities including resistance or strength training. Resistance exercise is a powerful anabolic stimulus that can modify the expression of critical regulatory genes associated with skeletal muscle growth and function, but this response may be impaired in aged individuals [24]. Incorporation of early mechanical stimulation in the form of resistance exercise is considered a critical determinant of ECM-bioscaffold-mediated skeletal muscle repair, but mechanical stimulation alone is increasingly becoming a therapeutic focus of skeletal muscle regeneration. White et al. [73] specifically showed that voluntary resistance wheel exercise significantly increased markers of mitochondrial and autophagosomal pathways and prevented age-related muscle wasting in 23-month-old mice. Mounting evidence has shown the importance of incorporation of mechanical loading to promote not only myogenesis, but also macrophage activation. Cezar et al. [74] corroborated the broad clinical utility of mechanical loading in the field of regenerative medicine by showing the ability of mechanical...
stimulation alone, in a biologic-free muscle-regenerating system, to promote myogenesis in a rodent model of ischemic muscle injury. Though perhaps not an ultimate solution, the combination of focused mechanical loading with stem-cell-, pharmaceutical-, or biomaterial-based therapies could potentially enhance regenerative outcomes.

Conclusions

Finding effective treatment strategies for sarcopenia will likely involve a multidisciplinary approach due to the complex etiology of the disease. Identification of the role of cytokines and small molecules, cellular metabolism, and endocrine-related changes have helped gain a better understanding of sarcopenia cause and progression. Regenerative medicine strategies, including the use of an acellular, inductive approach that tailors the microenvironment and considers the many cell types involved in efficient skeletal muscle regeneration, may provide a promising alternative to traditionally utilized therapies including stem cell delivery, pharmacological treatment, and physical rehabilitation. Likely, a combination of these approaches, among others, can provide improved outcomes for patients suffering from age-related loss.

Disclosure Statement

The authors have no conflict of interest to declare.

References


Age-Related Muscle Loss and Sarcopenia

Gerontology 2017;63:580–589
DOI: 10.1159/000479278


47 NRA, DZiKi/Badylak


